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Abstract
Hypertension is a major risk factor for stroke, cardiovascular disease, and end-stage renal disease, and its prevalence
is expected to rise dramatically. Effective hypertension management is thus critical. A particular priority is decreasing
the incidence of uncontrolled hypertension. Early identification of patients at risk for uncontrolled hypertension would
allow targeted use of personalized, proactive treatments. We develop machine learning models (logistic regression and
recurrent neural networks) to stratify patients with respect to the risk of exhibiting uncontrolled hypertension within
the coming three-month period. We trained and tested models using EHR data from 14,407 and 3,009 patients,
respectively. The best model achieved an AUROC of 0.719, outperforming the simple, competitive baseline of relying
prediction based on the last BP measure alone (0.634). Perhaps surprisingly, recurrent neural networks did not
outperform a simple logistic regression for this task, suggesting that linear models should be included as strong
baselines for predictive tasks using EHR.
Introduction
Hypertension is a major risk factor for stroke, cardiovascular disease, and end-stage renal disease. In the United States,
hypertension has substantial public health and economic implications: it affects 1 out of 3 adults and costs our health
system an estimated $46 billion each year1. Already a global scourge, the prevalence of hypertension is expected to
rise dramatically2. Successful management of hypertension is thus an important objective in light of the substantial
cost burden and high rate of adverse outcomes associated with uncontrolled hypertension, and will only increase in
importance in coming years. A guideline published by the American College of Cardiology defines uncontrolled
blood pressure as systolic ≥140 or diastolic ≥903. Medication non-adherence, unhealthy lifestyle factors, and failure
to up-titrate or add anti-hypertensive medications are significant contributors to uncontrolled hypertension.
Strategic and innovative solutions are needed to improve hypertension management, especially in primary care settings
where most patients with hypertension are managed1. Furthermore, owing to a shift to value-based health-care model,
achieving blood pressure control in hypertensive populations serves as an important quality measure for providers.
Patients at risk for uncontrolled hypertension stand to benefit from early identification as this can trigger proactive
treatment regimens and more aggressive education regarding lifestyle modification strategies, as well as use of sup-
portive technologies such as home-blood-pressure monitoring programs. However, some of these interventions are
costly and cannot be administered indiscriminately to all patients. Therefore, stratifying patients based on their indi-
vidual risk for uncontrolled hypertension could help providers make informed treatment decisions and in turn improve
long-term outcomes for hypertensive patients.
Prior work has shown that risk stratification can improve outcomes for high risk patients4, 5. To improve the clinical
impact on patients and cost-effectiveness of anti-hypertensive interventions, special attention has to be paid to manag-
ing high-risk patients identified through stratification methods4. Traditionally blood pressure (BP) was used to make
treatment decisions for managing hypertensive patients. However, recent studies indicate that BP alone is not sufficient
for making optimal treatment decisions. To make informed clinical decisions, clinicians should assess patient risk in
light of individual risk factors in addition to BP measurements4.
Beyond the clinical benefits of decreasing complications due to uncontrolled hypertension and resultant overall qual-
ity of life improvement, providers have other incentives to optimize treatment so as to minimize the prevalence of
uncontrolled blood pressure. Specifically, under value-based care models, achieving blood pressure control in hyper-
tensive populations is a quality measure (At-Risk Population Hypertension ACO #28). This metric determines the
extent to which Medicare reimburses health-care organizations at the end of a given financial year6. Accountable Care
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Figure 1: The cohort used excludes deceased patients; patients older than 90 and younger than 18; those with fewer
than 2 records in a year; and those with no vital sign records.
Organizations (ACOs) face significant financial penalties if more than half of their hypertensive population remain
uncontrolled at the end of the financial year7. Thus, hospitals and care providers have additional incentives to mitigate
uncontrolled hypertension and thus meet benchmark standards.
In closely related prior work upon which we build, Sun et al.8 developed and evaluated an ML model that predicts
transitions between controlled and uncontrolled hypertension and vice versa. Their task formulation is thus slightly
different from ours, as their focus is on identifying transition points rather than general risk stratification (i.e., whether
someone is likely to be uncontrolled or not in the near future, given current status and other variables extracted from
the EHR). But the motivation is ultimately the same. Our findings here largely support those of this prior work8, and
this study thus serves as further evidence, derived from a larger corpus, that ML can be used to aid management of
hypertension.
Objectives and contributions. The aim of this work is to empirically evaluate the feasibility of using ML to risk-
stratify patients with hypertension with respect to their likelihood of developing uncontrolled hypertension in a fixed
time window. Our contributions are as follows. We develop and evaluate models for predicting which patients are
likely to fall into the uncontrolled hypertension category within a window of 90 days from their last visit. Using a
dataset of EHR from over 27,000 hypertensive patients, we show that ML based approaches outperform the obvious
but competitive baseline of simply assuming no change will occur. This evaluation uses a dataset that is an order of
magnitude larger that used in prior work8. Also in contrast to this prior effort, we experiment with a modern RNN
architecture, namely LSTMs9. However we find that this does not consistently improve performance over a simple
logistic regression model.
Methods
Inclusion Criteria. This is a retrospective analysis of electronic health records (EHR) data. We collected data
from 27,195 hypertensive patients with approval from the Institutional Research Board (IRB) (protocol number
2016P001661) at Partners Healthcare. Data is from the period of 2010–2016, and includes patients with a primary
diagnosis of hypertension. We excluded from this pool patients who were deceased, older than 90, or under 18. We
also excluded patients with fewer than 2 records per fiscal year and/or those with no recorded vital sign data. Finally,
we excluded patients who did not have any records within 90 days of their last recorded encounter, as this was the
predictive window that we deemed operationally feasible. Note that this does imply a (potential) bias in our dataset:
we are training and evaluating our model on only those patients who had at least two visits within 90 days of each
other. This resulted in a corpus comprising 19,972 patients in total. Figure 1 provides a cohort selection flowchart.
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Figure 2: A schematic depicting the retrospective predictive task setup we consider. We acquired and cleaned EHR
data from all patients in our cohort and created targets that reflect their hypertension status in a ninety window from
point of prediction.
Patient Level
Demographic information Health history
Health information Vital information
Laboratory test results Co-morbidities
Medication information
Hospital Level
Admission information Clinician notes
Table 1: Features Categories in EHR data
Male Female Total
Train 6314 8093 14407
Validation 1176 1380 2556
Test 1742 1267 3009
Table 2: Dataset sample size statistics, in terms of num-
ber of patients.
Design and Feature Engineering We categorized EHR variables as patient level or hospital level; see Table 1. We
grouped patient records into encounters which included both inpatient and outpatient visits.
We extracted vitals, medication, health history, problem list and procedure(s) from the encounter records and labora-
tory orders. Similarly, we used medication codes from medication orders. Encounters are associated with diagnoses
lists, encoded as ICD9 and ICD10 codes that we also extracted. For patients with multiple diagnosis codes we con-
sidered the principal diagnosis. Medication, problems and lab test orders were coded using binary indicator variables.
We report all numerical variables and associated statistics in the Appendix.We separated the dataset into training, val-
idation, and testing at the patient level, i.e., these sets are disjoint with respect to the patients that they contain. We
summarize these dataset splits in Table 2.
For numeric variables (e.g., height, pulse) we replaced any missing values with averages taken over patients and/or
visits, as appropriate. Records with systolic and diastolic reading less than 90 and 60 respectively were excluded from
the study, as these indicate reading errors. The blood pressure fraction was defined as systolic over diastolic readings.
We included lab tests related to hypertension, on the basis of domain expertise. We dropped tests with total frequency
of less then 60 percent within total records.
Medications were categorized as: ACE Inhibitor, Diuretic, Beta Blocker, Antihypertensive drug, Calcium Channel
Blocker and Vasodilator (Table 5). All medications are reported in the Appendix. Numerical variables were scaled to
range [0, 1], using maximum and minimum values in the training set. Variables with more than 99 percent missing
Figure 3: LSTM model for processing visits in sequence.
values were dropped (see Appendix D and Appendix E). Categorical variables were converted to one-hot representation
(i.e., indicator vectors). We labeled patients with systolic BP above 140 or diastolic BP above 90 as uncontrolled and
others as controlled. Uncontrolled and controlled statuses were coded as 1 and 0, respectively. We fit our model on
the training set and chose hyperparameters using the validation set. Final model performances were evaluated on the
test set, which was completely held-out during development and validation.
The majority of patients (66%) have controlled hypertension at their target visit. This means our data exhibits class
imbalance; one target class is substantially more prevalent than another. This can make training discriminative models
tricky10. Here we adjusted class weights associated with targets during training for both models. Specifically, weights
for the respective classes were set inverse to their frequencies.
Setting. We aim to predict which patients will have controlled vs. uncontrolled blood pressure in the near-future,
operationally defined here as three months. We cast this as a binary classification task, and evaluated two standard
models for such tasks: Logistic Regression (LR) and Long Short Term Memory (LSTM) networks9. The latter is
a particular type of Recurrent Neural Network (RNN) which has been successfully applied to EHR data in prior
work11, 12, although to our knowledge not for hypertension specifically.
Experimental setup. Prior to any experimentation, we separated the data into training, validation and test sets. These
splits were at the patient level, i.e., each patient’s records appear in only one of the sets. The test set was used for final
evaluation but not used in any way during model development and tuning.
LSTMs consume sequences of inputs (in our case, a set of ordered vectors encoding information from each visit).
The number of prior visits to pass through the model is a hyperparameter. Using the validation set, we found 6 to be
the optimal number of records and fed as input sequence to the model. We zero-padded sequences corresponding to
patients with fewer than 6 encounter records. We thus modeled a patient’s sequence of records as x1, · · · , xT , where
each record xi ∈ RF is feature vector encoding F features. The hidden state obtained from the sequence records is
passed to a fully connected layer with sigmoid activation. Figure 3 depicts this schematically.
The LR model assumes a single fixed length vector as input from which to make predictions. Here we use this to
encode information extracted from the last patient record, combined with previous blood pressure measurements up to
six prior visits.
For parameter tuning in both models, we performed ad-hoc search over the validation set. The L1 regularizer was
chosen from range (1e-1,1e-6) and learning rate from range (1e-3, 1e-5). For the LSTM model, We first ran the model
using Adam optimizer with learning rate (1e-3) then we ran the model for the second time with learning rate of (1e-5).
Furthermore, the number of hidden nodes were optimized in range (6, 12, 80 , 120). Finally, batch size was chosen
from (128,256,512,1024).
The final optimized LSTM model has one hidden layer with 120 hidden nodes,dropout rate of 0.2 and 1e-5 penalty
for L1 kernel regularizer. The optimized LR model uses L1 regularization with a corresponding weight of 0.001 and
learning rate of 0.001.
All models were implemented using Keras13 version 2.2.2 with TensorFlow14 version 1.9.0 and trained on GPU. We
fit the LSTM using the RMSProp optimizer with binary cross entropy loss. For LR, we used the Adam15 optimizer.
Model Precision Recall F1 AUC
Baseline 0.674 0.671 0.672 0.634
LR 0.687 0.701 0.690 0.719
LSTM 0.696 0.713 0.700 0.714
Table 3: Results on the test set.
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Figure 4: ROC curves of each method over the test set.
We used early stopping criteria for assessing convergence, terminating training when loss decreased by≤ 10−7 on the
validation set. Under this criterion, the LR model trained for 500 epochs, and LSTM model ran for 250.
Results
We compared developed models against the natural baseline of using the patient’s BP measure from their most recent
(last) visit as the prediction for current visit. This is a reasonably competitive approach because hypertension status
exhibits strong auto-correlation, and our prediction window is relatively narrow (90 days.)
We report results on the test set in Table 3, also summarized in Figure 4.
To provide further insights into model predictions we inspect which variables are most responsible for the predictions
of a given model. In case of LR, a linear model, we simply rank features by (absolute) weight. We report the top
(highest weighted) 20 variables in Table 4a.
Inferring the importance of variables in LSTMs is not as straightforward, and multiple options for doing so exist. Here
we adopt a recently proposed method for analyzing deep neural networks, integrated gradients (IG)16. This method
provides a signed importance score for each variable that reflects its sum contribution to the output. More concretely,
for each data point this method calculates the integral of the gradient of output (i.e., y) with respect to each input
variable at each time step as we move said variable from the baseline of its current or observed value. If the output
changes significantly as we vary only one dimension (i.e., the absolute value of integral is large), the corresponding
variable is deemed important. For additional technical details, we refer the reader to the original paper16. We report
the top features for the LSTM inferred via IG in Table 4b. We report weights for the top 50 features for both models
in the Appendix.
Generally speaking, important features align with intuition. Blood pressure status (controlled vs uncontrolled encoded
as 0 and 1 respectively) and systolic BP measurements from prior visits are strongly predictive features in both models,
as would be expected.
Conclusion
All individuals involved in the various aspects of patient care stand to benefit from tools that aid informed clinical
decision making. From a provider’s perspective, identifying which hypertensive patients are likely to become (or
remain) uncontrolled can guide targeted, timely interventions and proactive tailored treatments. Thereby, preventing or
decreasing the incidence of adverse complications due to uncontrolled hypertension; and improving clinical outcomes
and reducing healthcare costs.
Accurate risk stratification model for hypertension may help increase clinical efficiency, reduce healthcare costs, and
improve overall quality of care delivered to hypertensive patients addressing a burgeoning problem in the US healthcare
system. This work has provided new evidence that ML models can perform this task using a comparatively large
Variable Name Weight
Systolic(t−1) 1.492
Systolic(t−2) 0.849
Systolic(t−3) 0.598
Blood Pressure(t−1) 0.550
Blood Pressure(t−2) 0.442
Systolic(t−4) 0.374
Blood Pressure(t−3) 0.349
Blood Pressure(t−4) 0.290
Systolic(t−6) 0.289
Blood Pressure(t−5) 0.268
Blood Pressure(t−6) 0.254
Systolic(t−5) 0.243
Blood Pressure(t−7) 0.226
Mets False -0.172
BloodLoss False -0.170
Systolic(t−7) 0.152
Smoker -0.152
Lymphoma False -0.132
HTN True -0.130
DSCOP -0.123
(a) Top 20 Variables for LR. Subscripts index prior visits.
Variable Name Importance
Time between visits(d) -0.068
Systolic(t−1) 0.024
Blood Pressure(t−2) 0.022
Blood Pressure(t−3) 0.019
Blood Pressure(t−1) 0.019
Blood Pressure(t−6 0.018
Blood Pressure(t−7) 0.018
Systolic(t−1) 0.015
Systolic(t−7) 0.013
White -0.013
Married/Partnered -0.013
Systolic(t−3) 0.012
Blood Pressure(t−4) 0.012
Depression False -0.012
Systolic(t−4) 0.012
Systolic(t−6) 0.011
Hypertension NOS -0.010
Blood Pressure(t−5) 0.010
BloodLoss False -0.008
Arrhythmia False -0.008
(b) Top 20 Variables for LSTM
dataset of patients, thus complementing existing related work on the problem8. We also find, perhaps somewhat
surprisingly, that a simple logistic regression model performs about the same as a complex RNN. Simple linear models
should always be considered as a strong baseline for predictive tasks over EHR.
Study limitations. This study has several important limitations, both technical and conceptual. First, due to the tran-
sition of the EHR system to EPIC, there was a gap between medical notes dates and the encounter dates. Therefore,
we were not able to use notes in the current work; incorporating these may improve the model. Second, this retro-
spective analysis means we had to winnow the set of patients included in the analysis for practical reasons (Figure
1). Third, for simplicity we replaced missing values with simple means, a naive form of imputation. More sophis-
ticated imputation methods, including Bayesian models17 and neural network imputation approaches18, may yield
improved performance17. We excluded the variables presented in Appendix E, due to a high proportion of missing
values (≥ 99%), which could adversely affect the performance of the model19. Few of these excluded variables are
likely to be clinically relevant, according to the domain experts involved in this project. Note that all patients had
varying numbers of missing values, but we did not exclude any of them based on missing values (rather, these were
simply imputed, as outlined above).
A final potential limitation of this work concerns our creation of target ‘labels’. To do so we required that patients in
our cohort had two visits within 90 days (so that the latter of these could serve as the target). This excluded 2,580
patients who did not meet this condition. This winnowing process may have induced a bias in the sample used for this
study, i.e., we cannot be certain that the resultant patient set is representative of the underlying population.
We have here demonstrated that one can achieve reasonably good predictive performance for this task. But if such
models are to be meaningfully used to inform care, a threshold for clinical action must be established in collaboration
with physicians.
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Appendix A Medications
Drug Family Types Drug Family Types
ACE Inhibitor Lisinopril, Benazepril Calcium channel blocker Amlodipine, Nifedipine
Diuretic Hydrochlorothiazide, Triamterene,Chlorothiazide, Antihypertensive drug Nifedipine, Irbesartan,Candesartan,Felodipine,
Hydrochlorothiazide/lisinopril, Chlortalidone Valsartan, Hydrochlorothiazide / Losartan,Telmisartan,
Hydrochlorothiazide/lisinopril, Losartan, Chlortalidon
Beta blocker Atenolol, Metoprolol, Nadolol, Labetalol, Bisoprolol, Vasodilator Hydralazine
Carvedilol
Table 5: Hypertensive Medication
Appendix B Results
VALIDATION SET
Model F1-SCORE PRECISION RECALL AUC
Male Female Total Male Female Total Male Female Total Total
Baseline 0.52 0.76 0.68 0.51 0.77 0.68 0.52 0.76 0.68 0.68
LR 0.50 0.80 0.70 0.58 0.76 0.70 0.43 0.84 0.70 0.72
LSTM 0.47 0.81 0.71 0.55 0.77 0.70 0.41 0.85 0.72 0.72
TEST SET
F1-SCORE PRECISION RECALL AUROC
Male Female Total Male Female Total Male Female Total Total
Baseline 0.51 0.75 0.67 0.50 0.76 0.67 0.52 0.74 0.67 0.63
LR 0.49 0.79 0.69 0.57 0.75 0.69 0.43 0.84 0.70 0.72
LSTM 0.47 0.80 0.70 0.55 0.76 0.70 0.41 0.85 0.71 0.71
Table 6: Model Performance per group
Appendix C Variables
Variable Name Count Mean Std Missing Variable Name Count Mean Std Missing
Heart Rate 2223 79.36 14.69 0.98 Lytes/Renal/Glucose 21973 1.00 0.00 0.79
Height 98151 66.82 19.91 0.08 Lytes/Renal/Glucose - POC 1273 1.00 0.00 0.99
Pulse 93769 75.32 13.56 0.12 Microscopic Sediment 2761 1.00 0.00 0.97
Respiratory Rate 22594 16.94 4.08 0.79 Other Hematology 2651 1.00 0.00 0.98
Temperature 51541 97.92 3.20 0.51 Routine Coagulation 2849 1.00 0.00 0.97
Weight 64057 185.58 46.09 0.40 Smear Morphology 1326 1.00 0.00 0.99
Systolic(t−1) 106125 133.30 17.26 0.00 Thyroid Studies 5758 1.00 0.00 0.95
Diastolic(t−1) 106064 75.92 10.67 0.00 Tumor Markers 2114 1.00 0.00 0.98
delta time 106125 36.12 25.10 0.00 Urinalysis 5640 1.00 0.00 0.95
BMI 40008 30.20 6.43 0.62 Urine Chemistries Random 3378 1.00 0.04 0.97
Fatigue (0-10) 3100 1.67 2.88 0.97 Blood Pressure(t−2) 106125 0.38 0.49 0.00
SexCD 106125 0.43 0.50 0.00 Systolic(t−2) 106106 134.51 17.98 0.00
Age As Of 2010 106125 61.93 13.57 0.00 Diastolic(t−2) 106033 76.46 11.15 0.00
BP Fraction(t−1) 106064 1.78 0.55 0.00 Blood Pressure(t−3) 106125 0.35 0.48 0.00
Age Year 76038 65.73 13.50 0.28 Systolic(t−3) 102869 133.90 17.60 0.03
Visit Number 76038 8.32 8.94 0.28 Diastolic(t−3) 102809 76.24 10.95 0.03
Acute Phase Reactants 1354 1.00 0.00 0.99 Blood Pressure(t−4) 106125 0.33 0.47 0.00
Anemia Related Studies 3188 1.00 0.00 0.97 Systolic(t−4) 99544 133.70 17.42 0.06
Blood Diff Absolute 11573 0.79 0.41 0.89 Diastolic(t−4) 99483 76.21 10.90 0.06
Blood Differential % 12425 0.73 0.44 0.88 Blood Pressure(t−5) 106125 0.32 0.47 0.00
Cardiac Tests 3241 1.00 0.00 0.97 Systolic(t−5) 96105 133.57 17.31 0.09
Complete Blood Count 14325 1.00 0.00 0.87 Diastolic(t−5) 96051 76.14 10.85 0.10
Endocrine Studies 7581 1.00 0.00 0.93 Blood Pressure(t−6) 106125 0.31 0.46 0.00
General Chemistries 23076 1.00 0.00 0.78 Systolic(t−6) 92725 133.55 17.29 0.13
Hepatitis 1195 0.99 0.10 0.99 Diastolic(t−6) 92670 76.13 10.85 0.13
Immunoglobulin 1179 1.00 0.00 0.99 Blood Pressure(t−7) 106125 0.30 0.46 0.00
Lipid Tests 7049 1.00 0.00 0.93 Systolic(t−7) 89242 133.49 17.27 0.16
Liver Function Tests 12213 1.00 0.00 0.89 Diastolic(t−7) 89188 76.10 10.88 0.16
Table 7: Variables statistics
Appendix D Variables Weights
Variable Name Weight
Systolic(t−1) 1.492
Systolic(t−2) 0.849
Systolic(t−3) 0.598
Blood Pressure(t−1) 0.550
Blood Pressure(t−2) 0.442
Systolic(t−4) 0.374
Blood Pressure(t−3) 0.349
Blood Pressure(t−4) 0.290
Systolic(t−6) 0.289
Blood Pressure(t−5) 0.268
Blood Pressure(t−6) 0.254
Systolic(t−5) 0.243
Blood Pressure(t−7) 0.226
Mets False -0.172
BloodLoss False -0.170
Systolic(t−7) 0.152
Smoker -0.152
Lymphoma False -0.132
HTN True -0.130
DSCOP -0.123
Drugs False -0.122
CHF True -0.105
Diastolic(t−7) -0.104
Heart Rate missing -0.103
Diastolic(t−1) 0.095
Blood Pressure(t−7) missing 0.095
Height missing 0.095
Blood Pressure(t−6) missing 0.089
Rheumatic False -0.083
PVD False -0.083
Systolix(t−6) missing 0.082
Blood Differential (%) -0.082
White -0.076
Blood Pressure(t−4) missing 0.072
PHSOTHER -0.069
Clinical referral -0.067
Paralysis False -0.064
Systolix(t−3) missing 0.064
Systolix(t−4) missing 0.062
PUD False -0.062
Systolix(t−7) missing 0.061
Anemia False -0.060
Fatigue (0-10) missing -0.057
Emergency Flag -0.054
DDCON -0.054
FluidsLytes False -0.052
MARRIED/PARTNERED -0.051
Alcohol False -0.051
Lisinopril -0.050
RaceGRP ASIAN -0.049
(a) LR Top 50 Variables Weights
Variable Name Weight
Time between visits(d) -0.068
Systolic(t−1) 0.024
Blood Pressure(t−2) 0.022
Blood Pressure(t−3) 0.019
Blood Pressure(t−1) 0.019
Blood Pressure(t−6 0.018
Blood Pressure(t−7) 0.018
Systolic(t−1) 0.015
Systolic(t−7) 0.013
White -0.013
Married/Partnered -0.013
Systolic(t−3) 0.012
Blood Pressure(t−4) 0.012
Depression False -0.012
Systolic(t−4) 0.012
Systolic(t−6) 0.011
Hypertension NOS -0.010
Blood Pressure(t−5) 0.010
BloodLoss False -0.008
Arrhythmia False -0.008
Systolic(t−5) 0.008
AgeAsOf2010 0.008
Respiratory rate missing 0.008
Hypertension NOS -0.007
Language English -0.007
Anemia False -0.007
Rheumatic False -0.007
Neuro/Other False -0.007
Temperature missing -0.007
PUD False -0.007
Weight Loss False -0.006
Mets False -0.006
DDCD Other -0.006
Liver False -0.006
Hypothyroid False -0.006
Atenolol -0.006
DMcx False -0.005
PVD True -0.005
AgeYearNBR 0.005
BMI missing 0.005
HIV False 0.005
Pulmonary False -0.005
Paralysis False -0.005
Diastolic(t−1) 0.005
Blood Diff Absolute missing -0.005
Obesity False -0.005
Coagulopathy False -0.005
Blood Differential 0.005
SexCD -0.004
Abdomnl pain -0.004
(b) LSTM Top 50 Variables Weights
Appendix E Dropped Variables
AAA (Abdominal Aortic Aneurysm ) Screening , ANA Screen , Albumin/creatinine ratio , Alcohol Drinks Per Week
, Alcohol Oz Per Week , Alcohol Use Screening , Amino Acids , Amino Acids, urine , Antibody Screen , Antiphos-
pholipid Antibodies , Antiphospholipid Antibody , Auto-Antibodies , B12 injection , Blood Gases/Oximetry , Blood
Pressure-LFA1162 , Blood Type , Body Surface Area (BSA) , Bone Marrow Stain , Bone density , Breast Exam ,
Breast Exam - LHA3537 , Breast Exam - LHA4003 , Breast Exam Instruction , CRYOs , CSF Chemistries , CSF
Counts and Diff , CSF/Fluid, Other , Calcium Requirements Recommendation , Carnitine, serum , Carnitine, urine ,
Chlamydia , Cholesterol , Cholesterol-HDL , Cholesterol-LDL , Cigarettes , Coagulation Factor Studies , Colonoscopy
, Complement , Complete Physical Exam , Condoms , Creatinine , Cystic Fibrosis Carrier , DNA Diagnostic Tests ,
DPT , DS Glucose , Dental Exams , Depo-provera Shot , Diet , Diphtheria and Tetanus booster (DT booster) , Do-
mestic Violence Screening , Drug Use Screening , Drugs A-E , Drugs F-N , Drugs O-Z , EGD (upper GI endoscopy)
, EKG , Echocardiogram , Exercise Advice , FEV1-pre (Pre-Forced Expiratory Volume) , FVC-pre (Pre-Forced Vital
Capacity) , Fetal Activity , Fluid Chemistries , Fluid Counts and Diff , Folic Acid Recommendation , Foot exam ,
Functional Status Screen , GFR (estimated) , Glucose , Gonorrhea , HCG (Human Chorionic Gonadotropin) , HCV
Ab-LHA3507 , HIVx , Haemophilus Influenzae type B (HIB) , Hand Gun Counseling , HbA1c (Hemoglobin A1c) ,
Hct (Hematocrit) , Head Circumference , Hearing , Hemocult x 3 , Hemoglobin Electrophoresis , Hepatitis A vaccine
(Hep A vac) , Hepatitis B vaccine (Hep B vac) , Hgb (Hemoglobin) , HgbAIC , Home Hemocult , Home glucose
monitoring , Hypercoagulation Studies , Hypoglycemia Assessment/Counseling , INR Result , Immune globulin ,
Inhibitors , Japanese encephalitis , KPS (Karnofsky performance status) , Liver - AST , Liver - Alkaline Phosphatase
, Liver - Total Bilirubin , Liver ALT , Lyme , Lyme vaccine , Lymph - % Difference , Lymph - Left Arm Volume ,
Lymph - Right Arm Volume , Mammogram , Measles, Mumps, Rubella (MMR) , Medicare Annual Wellness Visit ,
Meningococcal vaccine , Microalbumin , Nutrition Referral , O2 Saturation - LFA15000 , O2 Saturation - LFA15000.1
, O2 Saturation - LFA12575 , O2 Saturation - LFA38131 , O2 Saturation - LFA38132 , O2 Saturation - LFA4826 , O2
Saturation - LFA4828 , O2 Saturation - LFA5392 , O2 Saturation - SPO2 , OPV / IPV , On Oxygen? , Ophthalmology
Exam , Organic Acids, urine , PSA , Pain 0-10 , Pain Assessment , Pain Scale (0-10) , Pain Score , Pap Smear , Peak
Flow , Peak Flow - LHA4483 , Pelvic Exam , Personal Best Peak Flow , Platelet Aggregation , Platelet Antibodies
, Pneumovax , Podiatry exam , Positive Antibody Screen , Pregnancy Weight , Prepregnancy Height , Prepregnancy
Weight , Principal ICD Procedure CD , Prostate exam , Rabies , Rabies immune globulin , Rapid Strep , Rectal Exam
, Rh Factor , Routine Serology , Safe Sexual Practice Counseling , Seat belt counseling , Second hand smoke expo-
sure , Sigmoidoscopy , Smoking Quit Date , Smoking Start Date , Special Coagulation Interp , Stool Guaiac - 3 ,
Stool Guaiac-LHA4072 , T-cell Subsets , TSH-LHA18009 , Testicular Exam , Testicular Exam Instruction , Tetanus,
Diphtheria, accellular Pertussis vaccine , Tobacco Pack Per Day , Tobacco Used Years , Toxicology , Triglycerides ,
Trisomy 21 , Tuberculin purified protein derivative , Typhoid , UA-Protein , Urine Chemistries , Urine Chemistries
Timed , Urine Chemistries Unspec , Urine Culture , Urine Dip-LHA4935 , Urine Glucose , Urine Protein , Urine Toxi-
cology , VAS score , Varicella , Vision , Vision-Left Eye , Vision-Right Eye , Vitamin D (25 OH) , Weight Management
, Yellow fever .
Table 9: Variables dropped from consideration due to high proportion of missing values (> 99%)
